**Supplementary Table 1. Baseline characteristics of the study population.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Variables** | **Total** (N=358) | **GT1**  (N=163；45.5%) | **GT2**  (N=48；13.4%) | **GT3a**  (N=48；13.4%) | **GT3b**  (N=35；9.8%) | **GT6**  (N=44；12.3%) | **Unknown**  (N=20；5.6%) | P value |
| Age [M(IQR) | 56.6±11.3 | 58.9±11.2 | 59.0±12.7 | 52.2±9.57 | 49.4±8.7 | 54.0±9.57 | 58.3±10.1 | **<0.001** |
| Genders [N(%)]Male/Female | 228(63.7)/130(36.3) | 91(55.8)/72(44.2) | 24(50)/24(50) | 40(83.3)/8(16.7) | 26(74.3)/9(25.7) | 35(79.5)/9(20.5) | 12(60)/8(40) | **<0.001** |
| HCV viral load (×106 IU/L)MD (P25~P75) | 2.91 (0.69~7.94) | 3.83 (1.00~8.55) | 1.59 (0.34~5.94) | 2.91 (0.30~7.79) | 1.9 (1.01~6.68) | 3.23 (1.04~8.02) | 1.1 (0.05~10.10) | 0.169 |
| HBsAg [N(%)]Positive/Negative | 20(5.6)/338(94.4） | 9(5.5)/154(94.5) | 4(8.3)/44(91.7) | 1(2.1)/47(97.9) | 0(0)/35(100) | 4(9)/40(91) | 2(10)/18(90) | 0.272 |
| ANA [N(%)]Positive/Negative | 72(20.1)/286(79.9) | 35(21.5)/128(78.5) | 9(18.8)/39(81.2) | 9(18.8)/39(81.2) | 1(2.9)/34(97.1) | 11(25)/33(75) | 8(40)/12(60) | **0.018** |
| Fatty liver [N(%)]Yes/No | 80(22.3)/278(77.7) | 32(19.6)/131(80.4) | 8(16.7)/40(83.3) | 10(20.8)/38(79.2) | 13(37.1)/22(62.9) | 10(22.7)/34(77.3) | 7(35)/13(65) | 0.173 |
| Kidney injury [N(%)]Yes/No | 27(7.5)/331(92.5) | 12(7.4)/151(92.6) | 2(4.2)/46(95.8) | 5(10.4)/43(89.6) | 1(2.9)/34(97.1) | 4(9)/40(90.9) | 3(15)/17(85) | 0.496 |
| Liver transplantation [N(%)]Yes/No | 6(1.7)/352(98.3) | 2(1.2)/161(98.8) | 2(4.2)/46(95.8) | 0(0)/48(100) | 0(0)/35(100) | 0(0)/44(100) | 2(10)/18(90) | 0.068 |
| Liver cancer [N(%)] | | | | | | | | |
| ≥50 Y/O.Yes/No | 45(18.5)/198(81.5) | 18(14.1)/110(85.9) | 7(20.6)/27(79.4) | 10(41.7)/14(58.3) | 4(28.6)/10(71.4) | 2(7.4)/25(92.6) | 4(25)/12(75) | **0.017** |
| <50 Y/OYes/No | 5(4.3)/110(95.7) | 1(2.9)/34(97.1) | 1(7.1)/13(92.9) | 1(4.2)/23((95.8) | 1(4.8)/20(95.2) | 1(5.9)/16(94.1) | 0(0)/4(100) | 0.967 |
| Child-Pugh grade[N(%)] |  |  |  |  |  |  |  |  |
| ≥50Y/OB+C/A | 35(14.4）/208(85.6) | 11(8.6)/117(91.4) | 4(11.8)/30(88.2) | 7(29.2)/17(70.8) | 7(50)/7(50) | 2(7.1)/26(92.9) | 4(6.7)/11(73.3) | **<0.001** |
| <50 Y/O.B+C/A | 10(8.7)/105(91.3) | 3(8.6)/32(91.4) | 1(7.1)/13(92.9) | 2(8.3)/22(91.7) | 2(9.5)/19(90.5) | 3(18.8)/13(81.2) | 0(0)/5(100) | 0.888 |
| FIB-4[N(%)] | | | | | | | | |
| ≥50 Y/O.≥3.25/<3.25 | 95(39.1)/148(60.9) | 42(32.8)/86(67.2) | 14(41.2)/20(58.8) | 17(70.8)/7(29.2) | 7(50)/7(50) | 8(28.6)/20(71.4) | 7(46.7)/8(53.3) |  |
| <50 Y/O.≥3.25/<3.25 | 18(15.7)/97(84.3) | 1(2.9)/34(97.1) | 0(0)/14(100) | 6(25)/18(75) | 7(33.3)/14(66.7) | 4(25)/12(75) | 0(0)/5(100) | **0.004** |
| Metabolic disorders[N(%)] | | | | | | | | |
| HyperglycemiaWith/without | 30(8.4)/328(91.6) | 10(6.1)/153(93.9) | 6(12.5)/42(87.5) | 5(10.4)/43(89.6) | 1(2.9)/34(97.1) | 5(11.4)/39(88.6) | 3(15)/17(85) | 0.284 |
| HyperlipidemiaWith/without | 15(4.2)/343(95.8) | 4(2.5)/159(97.5) | 5(10.4)/43(89.6) | 2(4.2)/46(95.8) | 1(2.9)/34(97.1) | 1(2.3)/43(97.7) | 2(10)/18(90) | 0.12 |
| HyperuricemiaWith/without | 31(8.9)/317(91.1) | 14(8.6)/149(91.4) | 6(12.5)/42(87.5) | 4(8.3)/44(91.7) | 2(5.7)/33(94.3) | 4(9.1)/40(90.9) | 1(5)/19(95) | 0.93 |

Notes: Mean±SD refers to mean±standard deviation. M(P25~P75) referred to medium (25th percentile~75th percentile).The Wilcoxon rank sum test analyzed non-normal distribution measurement data. The measurement data that conform to normal distribution after variable transformation were analyzed by analysis of variance. Counting data were analyzed by Chi-square test.FIB-4: the fibrosis index based on four factors, FIB4=Age×AST/(Platelet×sqr(ALT). FIB-4 index Points>3.25 indicated cirrhosis most likely.Child A included CHC patients without cirrhosis which scored <=6. Child-Pugh stages B and C which scored >6 indicated advanced cirrhosis.ANA: anti-nuclear antibody